Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
Primary Purpose
Palmoplantar Psoriasis
Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
TEPSO cloth
Standard cloth
Sponsored by
About this trial
This is an interventional treatment trial for Palmoplantar Psoriasis focused on measuring psoriasis, soles, teflon
Eligibility Criteria
Inclusion Criteria:
- Palmoplantar psoriasis present for at least one year
- Symmetrical foot lesions with at least 5% of the skin surface involvement
- Difference less than or equal to 10% extension of lesions on both sides of the body
- Suspension for over 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)
Exclusion Criteria:
- Nonsymmetrical foot lesions or less than 5% of the skin surface involvement
- Difference of more than 10% extension of lesions on both sides of the body
- Patients who have performed, within 3 months before inclusion in the study, treatments with systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)
Sites / Locations
- Department of Dermatology, "Tor Vergata" general hospital
- Department of Dermatology, Fondazione S.Raffaele del monte Tabor
- Department of Dermatology, USL 4
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
TEPSO socks
Standard socks
Arm Description
This arm include all patients sides (left or right) treated with TEPSO socks.
This arm include all patients sides (left or right) treated with standard cotton socks.
Outcomes
Primary Outcome Measures
Percentage reduction of treated areas from baseline
Percentage reduction is based on standardized photos and computerized image evaluation
Secondary Outcome Measures
Quality of life
Quality of life is assessed by patient with visual analogue scale (VAS).
Full Information
NCT ID
NCT01197976
First Posted
September 8, 2010
Last Updated
September 26, 2011
Sponsor
Lenzi Egisto S.P.A.
1. Study Identification
Unique Protocol Identification Number
NCT01197976
Brief Title
Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
Official Title
Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Psoriasis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
September 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lenzi Egisto S.P.A.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of a special sock, manufactured using TEPSO®, compared to a normal cotton sock in the prognosis of symmetrical palmoplantar psoriasis present for at least one year.
Detailed Description
The clinical manifestations of palmoplantar psoriasis have an important impact on well being and quality of life. The manifestation of the disease is often exacerbated by factors such as significant physical and mechanical stress resulting from repeated and prolonged pressure over the affected areas and by everyday clothing. These problems have led the textile industry Lenzi Egisto S.p.A. to conduct some preliminary analyses to find a fabric that meets the specific needs of psoriatic patients in relation to everyday clothing. This preliminary study led to the creation of a particular fabric, TEPSO®, with features specific to the identified needs. This material consists essentially of PTFE (commercially known as Teflon®) and thus presents interesting characteristics that make it suitable for creating garments for patients with psoriasis:
Excellent flow properties and low surface friction
non-stick
Complete biocompatibility and chemical inertness
We can therefore speculate that in palmoplantar psoriasis high smoothness of the fabric and low coefficient of friction may translate into less discomfort felt by patients during normal physical activities, and into improved clinical course of the disease. In the end, it is expected that reduced mechanical compression and friction, would result into partial or complete clinical remission within a few weeks of use.
Therefore we propose to conduct a randomized controlled, double-blind, left-right clinical trial to assess the hypothesis that in palmoplantar psoriasis the use of TEPSO® could induce an improvement of disease and overall quality of life. To better assess the effects of treatment, the use of clothing in the study will be limited to symmetrical psoriatic lesions of feets in order to include areas that are comparable and relevant from a functional point of view.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Palmoplantar Psoriasis
Keywords
psoriasis, soles, teflon
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TEPSO socks
Arm Type
Experimental
Arm Description
This arm include all patients sides (left or right) treated with TEPSO socks.
Arm Title
Standard socks
Arm Type
Placebo Comparator
Arm Description
This arm include all patients sides (left or right) treated with standard cotton socks.
Intervention Type
Device
Intervention Name(s)
TEPSO cloth
Other Intervention Name(s)
Teflon
Intervention Description
TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Intervention Type
Device
Intervention Name(s)
Standard cloth
Other Intervention Name(s)
cotton
Intervention Description
Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Primary Outcome Measure Information:
Title
Percentage reduction of treated areas from baseline
Description
Percentage reduction is based on standardized photos and computerized image evaluation
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Quality of life
Description
Quality of life is assessed by patient with visual analogue scale (VAS).
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Palmoplantar psoriasis present for at least one year
Symmetrical foot lesions with at least 5% of the skin surface involvement
Difference less than or equal to 10% extension of lesions on both sides of the body
Suspension for over 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)
Exclusion Criteria:
Nonsymmetrical foot lesions or less than 5% of the skin surface involvement
Difference of more than 10% extension of lesions on both sides of the body
Patients who have performed, within 3 months before inclusion in the study, treatments with systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luigi Naldi, dermatology
Organizational Affiliation
Centro Studi Gised
Official's Role
Study Director
Facility Information:
Facility Name
Department of Dermatology, "Tor Vergata" general hospital
City
Rome
State/Province
Lazio
ZIP/Postal Code
00133
Country
Italy
Facility Name
Department of Dermatology, Fondazione S.Raffaele del monte Tabor
City
Milan
State/Province
Lombardy
ZIP/Postal Code
20132
Country
Italy
Facility Name
Department of Dermatology, USL 4
City
Prato
State/Province
Toscana
ZIP/Postal Code
59100
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
We'll reach out to this number within 24 hrs